Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laura Keller

Showing results (41-50 of 51) with videos related to

Pageof 6
Sort By:
Stem Cell Research|August 3, 2019
Antisense oligonucleotide therapy rescues aggresome formation in a novel spinocerebellar ataxia type 3 human embryonic stem cell lineLauren R Moore, Laura Keller, David D Bushart, et al.
Nature Communications|August 12, 2020
Developmental potential of aneuploid human embryos cultured beyond implantationMarta N Shahbazi, Tianren Wang, Xin Tao, et al.
Breast Cancer Research : BCR|January 24, 2013
RhoB modifies estrogen responses in breast cancer cells by influencing expression of the estrogen receptorClaire Médale-Giamarchi, Isabelle Lajoie-Mazenc, Emilie Malissein, et al.
Cancers|November 2, 2019
Intra-Patient Heterogeneity of Circulating Tumor Cells and Circulating Tumor DNA in Blood of Melanoma PatientsKatharina Gorges, Lisa Wiltfang, Tobias M Gorges, et al.
JCO Precision Oncology|January 20, 2022
Circulating Tumor DNA Allows Early Treatment Monitoring in BRAF- and NRAS-Mutant Malignant MelanomaJan Braune, Laura Keller, Florian Schiller, et al.
Advanced Biosystems|April 16, 2020
Evaluation of Microfluidic Ceiling Designs for the Capture of Circulating Tumor Cells on a Microarray PlatformHui-Yu Liu, Claudia Koch, Anna Haller, et al.
Clinical Chemistry|June 2, 2022
Expression Patterns and Corepressor Function of Retinoic Acid-induced 2 in Prostate CancerKatharina Besler, Aleksandra Węglarz, Laura Keller, et al.
Clinical Kidney Journal|May 18, 2026
Long-term citrate treatment in high-risk kidney stone formers is not associated with metabolic adverse effectsAlexander Ritter, Lea Bührer, Daniel G Fuster, et al.
Journal for Immunotherapy of Cancer|May 31, 2023
Prognostic value of von Willebrand factor levels in patients with metastatic melanoma treated by immune checkpoint inhibitorsJulia-Christina Stadler, Laura Keller, Christian Mess, et al.
EMBO Molecular Medicine|June 19, 2024
Mutation analysis in individual circulating tumor cells depicts intratumor heterogeneity in melanomaMark Sementsov, Leonie Ott, Julian Kött, et al.
Pageof 6

Showing results (41-50 of 51) with videos related to

Sort By:
Pageof 6
Stem Cell Research|August 3, 2019
Antisense oligonucleotide therapy rescues aggresome formation in a novel spinocerebellar ataxia type 3 human embryonic stem cell lineLauren R Moore, Laura Keller, David D Bushart, et al.
Nature Communications|August 12, 2020
Developmental potential of aneuploid human embryos cultured beyond implantationMarta N Shahbazi, Tianren Wang, Xin Tao, et al.
Breast Cancer Research : BCR|January 24, 2013
RhoB modifies estrogen responses in breast cancer cells by influencing expression of the estrogen receptorClaire Médale-Giamarchi, Isabelle Lajoie-Mazenc, Emilie Malissein, et al.
Cancers|November 2, 2019
Intra-Patient Heterogeneity of Circulating Tumor Cells and Circulating Tumor DNA in Blood of Melanoma PatientsKatharina Gorges, Lisa Wiltfang, Tobias M Gorges, et al.
JCO Precision Oncology|January 20, 2022
Circulating Tumor DNA Allows Early Treatment Monitoring in BRAF- and NRAS-Mutant Malignant MelanomaJan Braune, Laura Keller, Florian Schiller, et al.
Advanced Biosystems|April 16, 2020
Evaluation of Microfluidic Ceiling Designs for the Capture of Circulating Tumor Cells on a Microarray PlatformHui-Yu Liu, Claudia Koch, Anna Haller, et al.
Clinical Chemistry|June 2, 2022
Expression Patterns and Corepressor Function of Retinoic Acid-induced 2 in Prostate CancerKatharina Besler, Aleksandra Węglarz, Laura Keller, et al.
Clinical Kidney Journal|May 18, 2026
Long-term citrate treatment in high-risk kidney stone formers is not associated with metabolic adverse effectsAlexander Ritter, Lea Bührer, Daniel G Fuster, et al.
Journal for Immunotherapy of Cancer|May 31, 2023
Prognostic value of von Willebrand factor levels in patients with metastatic melanoma treated by immune checkpoint inhibitorsJulia-Christina Stadler, Laura Keller, Christian Mess, et al.
EMBO Molecular Medicine|June 19, 2024
Mutation analysis in individual circulating tumor cells depicts intratumor heterogeneity in melanomaMark Sementsov, Leonie Ott, Julian Kött, et al.
Pageof 6